Core Viewpoint - The recent public endorsement of ergotinine by Liu Gexin, chairman of Kelong Pharmaceutical, has sparked significant interest in the A-share market, particularly in stocks related to ergotinine, leading to substantial price increases for several companies [2][8]. Group 1: Market Reaction - Following Liu Gexin's public display of fitness and claims of long-term ergotinine use, stocks such as Liren Lizhuang, Chuaning Biological, and Tuoxin Pharmaceutical experienced notable price surges, with Liren Lizhuang hitting the daily limit for two consecutive trading days [2][8]. - As of May 16, Liren Lizhuang's stock price reached 9.43 yuan per share, with a total market capitalization of 3.776 billion yuan [7]. Group 2: Company Responses - Liren Lizhuang confirmed that it has no undisclosed significant information and noted that its product containing ergotinine, "Qianjin Jiguang Drink," contributes minimally to overall revenue [4][7]. - Other companies, such as Wanbang Pharmaceutical and Fushijia, have responded to investor inquiries regarding their involvement with ergotinine, indicating ongoing research and exploration of its potential benefits [8]. Group 3: Ergotinine Overview - Ergotinine, discovered in 1909, is recognized as a potent antioxidant with various physiological functions, including free radical scavenging and cellular protection [7]. - The compound has applications across multiple industries, including cosmetics and health foods, with increasing recognition in the market, although awareness remains low domestically [7][8].